α-Methylacyl-CoA racemase - An 'obscure' metabolic enzyme takes centre stage

FEBS Journal

Volumn 275, Issue 6, 2008, Pages 1089-1102

  Lloyd, Matthew D ^a   Darley, Daniel J ^a   Wierzbicki, Anthony S ^b   Threadgill, Michael D ^a  

^a University of Bath   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

methylacyl CoA racemase (AMACR); oxidation; oxidation; oxidation; Branched chain fatty acid oxidation; Ibuprofen; P504S; Peroxisomes; Phytanic acid; Prostate cancer

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CARBON; COENZYME A; LIPID; METHYL GROUP; PHYTANIC ACID;

BREAST CANCER; CATALYSIS; COLON CANCER; DIET; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME STRUCTURE; FAT INTAKE; FATTY ACID OMEGA OXIDATION; FATTY ACID OXIDATION; HUMAN; LIPID METABOLISM; MITOCHONDRION; NEUROLOGIC DISEASE; NONHUMAN; OXIDATION; PEROXISOME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RESEARCH; REVIEW; RISK FACTOR; TREATMENT PLANNING;

ANIMALS; DIET; FATTY ACIDS; HUMANS; NEOPLASMS; RACEMASES AND EPIMERASES;

EID: 40349098747     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06290.x     Document Type: Review

References (124)

1. Mukherji M, Schofield CJ, Wierzbicki AS, Jansen GA, Wanders RJA Lloyd MD (2003) The chemical biology of branched-chain lipid metabolism. Prog Lipid Res 42, 359 376.
2. Wierzbicki AS, Lloyd MD, Schofield CJ, Feher MD Gibberd FB (2002) Refsum's disease: a peroxisomal disorder affecting phytanic acid α-oxidation. J Neurochem 80, 727 735.
3. Wanders RJA, Jansen GA Lloyd MD (2003) Phytanic acid α-oxidation, new insights into an old problem: a review. Biochim Biophys Acta 1631, 119 135.
4. Wanders RJA, Van Roermund CWT, Visser WF, Ferdinandusse S, Jansen GA, Van Den Brink DM, Gloerich J Waterham HR (2003) Peroxisomal fatty acid α- and β-oxidation in health and disease: new insights. In Peroxisomal Disorders and Regulation of Genes (Roels F, Baes M De Bie S, eds pp. 293 302. Kluwer Academic, New York, NY.
5. Verhoeven NM Jakobs C (2001) Human metabolism of phytanic acid and pristanic acid. Prog Lipid Res 40, 453 466.
6. Verhoeven NM, Wanders RJA, Poll-The BT, Saudubray JM Jakobs C (1998) The metabolism of phytanic acid and pristanic acid in man: a review. J Inherit Metabol Dis 21, 697 728.
7. Seedorf U (1998) Peroxisomes in lipid metabolism. J Cell Biochem Supplement 30-31, 158 167.
8. Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB Moser HW (2006) Peroxisome biogenesis disorders. Biochim Biophys Acta Mol Cell Res 1763, 1733 1748.
9. Wanders RJA Waterham HR (2006) Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim Biophys Acta Mol Cell Res 1763, 1707 1720.
10. Jansen GA Wanders RJA (2006) Alpha-oxidation. Biochim Biophys Acta Mol Cell Res 1763, 1403 1412.
11. Thornburg T, Turner AR, Chen YQ, Vitolins M, Chang B Xu J (2006) Phytanic acid, AMACR and prostate cancer risk. Future Oncol 2, 213 223.
12. Evans AJ (2003) α-Methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 56, 892 897.
13. McDonough MA, Kavanagh KL, Butler D, Searls T, Oppermann U Schofield CJ (2005) Structure of human phytanoyl-CoA 2-hydroxylase identifies molecular mechanisms of Refsum disease. J Biol Chem 280, 41101 41110.
14. Mukherji M, Chien W, Kershaw NJ, Clifton IJ, Schofield CJ, Wierzbicki AS Lloyd MD (2001) Structure-function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum's disease. Hum Mol Genet 10, 1971 1982.
15. Schliebs W Kunau WH (2006) PTS2 co-receptors: diverse proteins with common features. Biochim Biophys Acta Mol Cell Res 1763, 1605 1612.
16. Searls T, Butler D, Chien W, Mukherji M, Lloyd MD Schofield CJ (2005) Studies on the specificity of unprocessed and mature forms of phytanoyl-CoA 2-hydroxylase and mutation of the iron binding ligands. J Lipid Res 46, 1660 1667.
17. Mukherji M, Kershaw NJ, MacKinnon CH, Clifton IJ, Wierzbicki AS, Schofield CJ Lloyd MD (2001) 'Chemical co-substrate rescue' of phytanoyl-CoA 2-hydroxylase mutants causing Refsum's disease. Chem Commun 2001, 972 973.
18. Prescott AG Lloyd MD (2000) The iron(II), 2-oxoacid-dependent oxygenases and their role in metabolism. Nat Prod Rep 17, 367 383.
19. Foulon V, Asselberghs S, Geens W, Mannaerts GP, Casteels M Van Veldhoven PP (2003) Further studies on the substrate spectrum of phytanoyl-CoA hydroxylase: implications for Refsum disease? J Lipid Res 44, 2349 2355.
20. Foulon V, Sniekers M, Huysmans E, Asselberghs S, Mahieu V, Mannaerts GP, Van Veldhoven PP Casteels M (2005) Breakdown of 2-hydroxylated straight chain fatty acids via peroxisomal 2-hydroxyphytanoyl-CoA lyase. J Biol Chem 280, 9802 9812.
21. Mukherji M, Kershaw NJ, Schofield CJ, Wierzbicki AS Lloyd MD (2002) Utilization of sterol carrier protein-2 by phytanoyl-CoA 2-hydroxylase in the peroxisomal α-oxidation of phytanic acid. Chem Biol 9, 597 605.
22. van den Brink DM, van Miert JM Wanders RJA (2005) A novel assay for the prenatal diagnosis of Sjogren-Larsson syndrome. J Inherit Metab Dis 28, 965 969.
23. Reference withdrawn.
24. van den Brink DM, van Miert JM Wanders RJA (2005) Assay for Sjogren-Larsson syndrome based on a deficiency of phytol degradation. Clin Chem 51, 240 242 (Corrigendum appears in Clin Chem51, 1566).
25. van den Brink DM, van Miert JNI, Dacremont G, Rontani JF, Jansen GA Wanders RJA (2004) Identification of fatty aldehyde dehydrogenase in the breakdown of phytol to phytanic acid. Mol Genet Metab 82, 33 37.
26. van den Brink DM, van Miert JNI, Dacremont G, Rontani JF Wanders RJA (2005) Characterization of the final step in the conversion of phytol into phytanic acid. J Biol Chem 280, 26838 26844.
27. van den Brink DM Wanders RJA (2006) Phytanic acid: production from phytol, its breakdown and role in human disease. Cell Mol Life Sci 63, 1752 1765.
28. Rizzo WB (1998) Inherited disorders of fatty alcohol metabolism. Mol Genet Metab 65, 63 73.
29. Lloyd MD, Boardman KDE, Smith A, van den Brink DM, Wanders RJA Threadgill MD (2007) Characterisation of recombinant human fatty aldehyde dehydrogenase: implications for Sjögren-Larsson syndrome. J Enzyme Inhib Med Chem 22, 584 590.
30. Gloerich J, Ruiter JPN, van den Brink DM, Ofman R, Ferdinandusse S Wanders RJA (2006) Peroxisomal trans-2-enoyl-CoA reductase is involved in phytol degradation. FEBS Lett 580, 2092 2096.
31. Wierzbicki AS (2004) Clinical significance of oxidation from phytol to phytanic acid in man. Mol Genet Metab 83, 347 347.
32. Allen NE, Grace PB, Ginn A, Travis RC, Roddam AW, Appleby PN Key T (2007) Phytanic acid: measurement of plasma concentrations by gas-liquid chromatography-mass spectrometery analysis and associations with diet and other plasma fatty acids. Br J Nutr, doi :.
33. Verhoeven NM, Jakobs C, Carney G, Somers MP, Wanders RJA Rizzo WB (1998) Involvement of microsomal fatty aldehyde dehydrogenase in the α-oxidation of phytanic acid. FEBS Lett 429, 225 228.
34. Jansen GA, van den Brink DM, Ofman R, Draghici O, Dacremont G Wanders RJA (2001) Identification of pristanal dehydrogenase activity in peroxisomes: conclusive evidence that the complete phytanic acid α-oxidation pathway is localized in peroxisomes. Biochem Biophys Res Commun 283, 674 679.
35. Kelson TL, McVoy JRS Rizzo WB (1997) Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. Biochim Biophys Acta 1335, 99 110.
36. Rizzo WB, Lin Z Carney G (2001) Fatty aldehyde dehydrogenase: genomic structure, expression and mutation analysis in Sjogren-Larsson syndrome. Chem Biol Interact 130, 297 307.
37. Lin ZL, Carney G Rizzo WB (2000) Genomic organization, expression, and alternate splicing of the mouse fatty aldehyde dehydrogenase gene. Mol Genet Metab 71, 496 505.
38. Ashibe B, Hirai T, Higashi K, Sekimizu K Motojima K (2007) Dual subcellular localization in the endoplasmic reticulum and peroxisomes and a vital role in protecting against oxidative stress of fatty aldehyde dehydrogenase are achieved by alternative splicing. J Biol Chem 282, 20763 20773.
39. Motojima K Hirai T (2006) Peroxisome proliferator-activated receptor alpha plays a vital role in inducing a detoxification system against plant compounds with crosstalk with other xenobiotic nuclear receptors. FEBS J 273, 292 300.
40. Wierzbicki AS, Mayne PD, Lloyd MD, Burston D, Mei G, Sidey MC, Feher MD Gibberd FB (2003) Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease. J Lipid Res 44, 1481 1488.
41. Komen JC, Duran M Wanders RJA (2004) ω-Hydroxylation of phytanic acid in rat liver microsomes: implications for Refsum disease. J Lipid Res 45, 1341 1346.
42. Komen JC, Duran M Wanders RJA (2005) Characterization of phytanic acid ω-hydroxylation in human liver microsomes. Mol Genet Metab 85, 190 195.
43. Komen JC Wanders RJA (2006) Identification of the cytochrome P450 enzymes responsible for the ω-hydroxylation of phytanic acid. FEBS Lett 580, 3794 3798.
44. Xu FY, Ng VY, Kroetz DL de Montellano PRO (2006) CYP4 isoform specificity in the ω-hydroxylation of phytanic acid, a potential route to elimination of the causative agent of Refsum's disease. J Pharmacol Exp Ther 318, 835 839.
45. Ferdinandusse S Houten SM (2006) Peroxisomes and bile acid biosynthesis. Biochim Biophys Acta Mol Cell Res 1763, 1427 1440.
46. Schmitz W Conzelmann E (1997) Stereochemistry of peroxisomal and mitochondrial β-oxidation of α-methylacyl-CoAs. Eur J Biochem 244, 434 440.
47. Ferdinandusse S, Overmars H, Denis S, Waterham HR, Wanders RJA Vreken P (2001) Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal α-methylacyl-CoA racemase deficiency. J Lipid Res 42, 137 141.
48. Van Veldhoven PP, Meyhi E, Squires RH, Fransen M, Fournier B, Brys V, Bennett MJ Mannaerts GP (2001) Fibroblast studies documenting a case of peroxisomal 2-methylacyl-CoA racemase deficiency: possible link between racemase deficiency and malabsorption and vitamin K deficiency. Eur J Clin Invest 31, 714 722.
49. Ferdinandusse S, Denis S, Clayton PT, Graham A, Rees JE, Allen JT, McLean BN, Brown AY, Vreken P, Waterham HR et al. (2000) Mutations in the gene encoding peroxisomal α-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Genet 24, 188 191.
50. Ferdinandusse S, Rusch H, van Lint AEM, Dacremont G, Wanders RJA Vreken P (2002) Stereochemistry of the peroxisomal branched-chain fatty acid α- and β-oxidation systems in patients suffering from different peroxisomal disorders. J Lipid Res 43, 438 444.
51. Savolainen K, Kotti TJ, Schmitz W, Savolainen TI, Sormunen RT, Ilves M, Vainio SJ, Conzelmann E Hiltunen JK (2004) A mouse model for α-methylacyl-CoA racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methyl-branched lipids. Hum Mol Genet 13, 955 965.
52. Shieh WR Chen CS (1993) Purification and characterization of novel 2-arylpropionyl-CoA epimerases from rat-liver cytosol and mitochondria. J Biol Chem 268, 3487 3493.
53. Shieh WR, Gou DM, Liu YC, Chen CS Chen CY (1993) A C-13 NMR study on ibuprofen metabolism in isolated rat-liver mitochondria. Anal Biochem 212, 143 149.
54. Hall SD Qian XT (1994) The role of coenzyme A in the biotransformation of 2-arylpropionic acids. Chem Biol Interact 90, 235 251.
55. Chen CS, Chen TL Shieh WR (1990) Metabolic stereoisomeric inversion of 2-arylpropionic acids - on the mechanism of ibuprofen epimerization in rats. Biochim Biophys Acta 1033, 1 6.
56. Chen CS, Shieh WR, Lu PH, Harriman S Chen CY (1991) Metabolic stereoisomeric inversion of ibuprofen in mammals. Biochim Biophys Acta 1078, 411 417.
57. Reichel C, Bang H, Brune K, Geisslinger G Menzel S (1995) 2-Arylpropionyl-CoA epimerase: partial peptide sequences and tissue localization. Biochem Pharmacol 50, 1803 1806.
58. Reichel C, Brugger R, Bang H, Geisslinger G Brune K (1997) Molecular cloning and expression of a 2-arylpropionyl-coenzyme A epimerase: a key enzyme in the inversion metabolism of ibuprofen. Mol Pharmacol 51, 576 582.
59. Knihinicki RD, Day RO Williams KM (1991) Chiral inversion of 2-arylpropionic acid nonsteroidal antiinflammatory drugs. 2. Racemization and hydrolysis of (R)-ibuprofen-CoA and (S)-ibuprofen-CoA thioesters. Biochem Pharmacol 42, 1905 1911.
60. Jiang Z, Woda BA, Rock KL, Xu YD, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P et al. (2001) P504S - a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25, 1397 1404.
61. Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, Xu JC Chu PGG (2003) Expression of α-methylacyl-CoA racemase (P504S) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 34, 792 796.
62. Luo J, Hicks J, Gage WR, Wanders RJ, Isaacs WB De Marzo AM (2002) Overexpression of α-methylacyl-CoA racemase (AMACR) in prostate cancer. J Urol 167, 57 58.
63. Jiang Z, Fanger GR, Banner BF, Woda BA, Algate P, Dresser K, Xu JC, Reed SG, Rock KL Chu PG (2003) A dietary enzyme: α-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev 27, 422 426.
64. Jiang Z, Woda BA, Wu CL Yang XMJ (2004) Discovery and clinical application of a novel prostate cancer marker - α-methylacyl CoA racemase (P504S). Am J Clin Pathol 122, 275 289.
65. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CN, Platz EA, Ferdinandusse S, Wanders RJ et al. (2002) α-Methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62, 2220 2226.
66. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM Isaacs WB (2003) α-Methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 63, 7365 7376.
67. Yang XJ, Wu C-L, Woda BA, Dresser K, Tretiakova M, Fanger GR Jiang Z (2002) Expression of α-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 26, 921 925.
68. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T et al. (2004) Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene expression profiles of prostate cancers and PINs. Cancer Res 64, 5963 5972.
69. Witkiewicz AK, Varambally S, Shen RL, Mehra R, Sabel MS, Ghosh D, Chinnaiyan AM, Rubin MA Kleer CG (2005) α-Methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. Cancer Epidemiol Biomarkers Prev 14, 1418 1423.
70. Chen Y-T, Tu JJ, Kao J, Zhou XK Mazumdar M (2005) Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res 11, 6558 6566.
71. Gupta A, Wang HLL, Policarpio-Nicolas ML, Tretiakova MS, Papavero V, Pins MR, Jiang Z, Humphrey PA, Cheng L Yang XMJ (2004) Expression of α-methylacyl-coenzyme A racemase in nephrogenic adenoma. Am J Surg Pathol 28, 1224 1229.
72. Went PT, Sauter G, Oberholzer M Bubendorf L (2006) Abundant expression of AMACR in many distinct tumour types. Pathology 38, 426 432.
73. Xu JF, Thornburg T, Turner AR, Vitolins M, Case D, Shadle J, Hinson L, Sun JL, Liu WN, Chang BL et al. (2005) Serum levels of phytanic acid are associated with prostate cancer risk. Prostate 63, 209 214.
74. Mobley JA, Leav I, Zielie P, Wotkowitz C, Evans J, Lam YW, L'Esperance BS, Jiang Z Ho S (2003) Branched fatty acids in dairy and beef products markedly enhance α-methylacyl-CoA racemase expression in prostate cancer cells in vitro. Cancer Epidemiol Biomarkers Prev 12, 775 783.
75. Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA et al. (2004) Elevated α-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol 164, 787 793.
76. Zha S Issacs WB (2005) A nonclassical CCAAT enhancer element binding protein binding site contributes to α-methylacyl-CoA racemase expression in prostate cancer. Mol Cancer Res 3, 110 118.
77. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJA, Luo J, De Marzo AM Issacs WB (2005) Peroxisomal branched-chain fatty acid β-oxidation pathway is upregulated in prostate cancer. Prostate 63, 316 323.
78. Zheng S, Chang BL, Isaacs SD, Wiley KE, Turner AR, Hawkins GA, Bleecker ER, Walsh PC, Meyers DA, Isaacs W et al. (2002) Novel germline mutations in the gene coding for α-methylacyl-CoA racemase may associated with prostate cancer risk. Am J Hum Genet 71, 420.
79. Levin AM, Zuhlke KA, Ray AM, Cooney KA Douglas JA (2007) Sequence variation in α-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer. Prostate 67, 1507 1513.
80. Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB, Chatterjee N, Welch R, Huang WY Hayes RB (2007) Variants in the α-methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev 16, 1536 1542.
81. Shen-Ong GL, Feng Y Troyer DA (2003) Expression profiling identifies a novel α-methylacyl-CoA racemase exon with fumarate hydratase homology. Cancer Res 63, 3296 3301.
82. Mubiru JN, Shen-Ong GL, Valente AJ Troyer DA (2004) Alternative spliced variants of the α-methylacyl-CoA racemase gene and their expression in prostate cancer. Gene 327, 89 98.
83. Mubiru JN, Valente AJ Troyer DA (2005) A variant of α-methylacyl- CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer. Prostate 65, 117 123.
84. Amery L, Fransen M, De Nys K, Mannaerts GP Van Veldhoven PP (2000) Mitochondrial and peroxisomal targeting of 2-methylacyl-CoA racemase in humans. J Lipid Res 41, 1752 1759.
85. Ferdinandusse S, Denis S, Ijlst L, Dacremont G, Waterham HR Wanders RJA (2000) Subcellular localization and physiological role of α-methylacyl-CoA racemase. J Lipid Res 41, 1890 1896.
86. Kotti TJ, Savolainen K, Helander HM, Yagi A, Novikov DK, Kalkkinen N, Conzelmann E, Hiltunen JK Schmitz W (2000) In mouse α-methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes. J Biol Chem 275, 20887 20895.
87. Schmitz W, Fingerhut R Conzelmann E (1994) Purification and properties of an α-methylacyl-CoA racemase from rat liver. Eur J Biochem 222, 313 323.
88. Schmitz W, Albers C, Fingerhut R Conzelmann E (1995) Purification and characterization of an α-methylacyl-CoA racemase from human liver. Eur J Biochem 231, 815 822.
89. Richard JP Amyes TL (2001) Proton transfer at carbon. Curr Opin Chem Biol 5, 626 633.
90. Savolainen K, Bhaumik P, Schmitz W, Kotti TJ, Conzelmann E, Wierenga RK Hiltunen JK (2005) α-Methylacyl-CoA racemase from Mycobacterium tuberculosis: mutational and structural characterization of the active site and the fold. J Biol Chem 280, 12611 12620.
91. Bhaumik P, Schmitz W, Hassinen A, Hiltunen JK, Conzelmann E Wierenga RK (2007) The catalysis of the 1,1-proton transfer by α-methyl-acyl-CoA racemase is coupled to a movement of the fatty acyl moiety over a hydrophobic, methionine-rich surface. J Mol Biol 367, 1145 1161.
92. Heider J (2001) A new family of CoA-transferases. FEBS Lett 509, 345 349.
93. Gruez A, Roig-Zamboni V, Valencia C, Campanacci VR Cambillau C (2003) The crystal structure of the Escherichia coli YfdW gene product reveals a new fold of two interlaced rings identifying a wide family of CoA transferases. J Biol Chem 278, 34582 34586.
94. Jonsson S, Ricagno S, Lindqvist Y Richards NGJ (2004) Kinetic and mechanistic characterization of the formyl-CoA transferase from Oxalobacter formigenes. J Biol Chem 279, 36003 36012.
95. Lee KS, Park SM, Rhee KH, Bang WG, Hwang K Chi YM (2006) Crystal structure of fatty acid-CoA racemase from Mycobacterium tuberculosis H37Rv. Proteins Struct Funct Bioinformatics 64, 817 822.
96. Carnell AJ, Hale I, Denis S, Wanders RJA, Isaacs WB, Wilson BA Ferdinandusse S (2007) Design, synthesis, and in vitro testing of α-methylacyl-CoA racemase inhibitors. J Med Chem 50, 2700 2707.
97. Schrader M Fahimi HD (2006) Peroxisomes and oxidative stress. Biochim Biophys Acta Mol Cell Res 1763, 1755 1766.
98. Shyadehi AZ Harding JJ (2002) Protective effects of ibuprofen and its major metabolites against in vitro inactivation of catalase and fumarase: relevance to cataracts. Biochim Biophys Acta 1587, 31 35.
99. Wolfrum C, Borrmann CM, Borchers T Spener F (2001) Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci USA 98, 2323 2328.
100. Wolfrum C, Ellinghaus P, Fobker M, Seedorf U, Assmann G, Borchers T Spener F (1999) Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J Lipid Res 40, 708 714.
101. Wolfrum C Spener F (2001) Chlorophyll-derived fatty acids regulate expression of lipid metabolizing enzymes in liver - a nutritional opportunity. Ocl Oleagineux Corps Gras Lipides 8, 39 44.
102. Zomer AWM, Jansen GA, van der Burg B, Verhoeven NM, Jakobs C, van der Saag PT, Wanders RJA Poll-The T (2000) Phytanoyl-CoA hydroxylase activity is induced by phytanic acid. Eur J Biochem 267, 4063 4067.
103. Zomer AWM, van der Burg B, Jansen GA, Wanders RJA, Poll-The BT van der Saag PT (2000) Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferater-activated receptor-α. J Lipid Res 41, 1801 1807.
104. Zomer AWM, Van Der Saag PT Poll-The BT (2003) Phytanic and pristanic acid are naturally occuring ligands. In Peroxisomal Disorders and Regulation of Genes (Roels F, Baes M De Bie S, eds pp. 247 254. Kluwer Academic, New York, NY.
105. Seedorf U, Ellinghaus P, Glass B Assmann G (1997) Regulation of PPAR-α function by dietary phytanic acid in normal and Sep α-deficient mice. Circulation 96, 3700 3700.
106. Hostetler HA, Kier AB Schroeder F (2006) Very-long-chain and branched-chain fatty acyl-CoAs are high affinity ligands for the peroxisome proliferator-activated receptor alpha (PPAR-α). Biochemistry 45, 7669 7681.
107. Hostetler HA, Petrescu AD, Kier AB Schroeder F (2005) Peroxisome proliferator-activated receptor-α interacts with high affinity and is conformationally responsive to endogenous ligands. J Biol Chem 280, 18667 18682.
108. Heim M, Johnson J, Boess F, Bendik I, Weber P, Hunziker W Fluhmann B (2002) Phytanic acid, a natural peroxisome proliferator-activated receptor agonist, regulates glucose metabolism in rat primary hepatocytes. FASEB J 16, 718 720.
109. Ellinghaus P, Wolfrum C, Assmann G, Spener F Seedorf U (1999) Phytanic acid activates the peroxisome proliferator-activated receptor-α (PPAR-α) in sterol carrier protein 2- sterol carrier protein x-deficient mice. J Biol Chem 274, 2766 2772.
110. Gloerich J, van den Brink DM, Ruiter JPN, van Vlies N, Vaz FM, Wanders RJA Ferdinandusse S (2007) Metabolism of phytol to phytanic acid in the mouse, and the role of PPAR-α in its regulation. J Lipid Res 48, 77 85.
111. Goto T, Takahashi N, Kato S, Egawa K, Ebisu S, Moriyama T, Fushiki T Kawada T (2005) Phytol directly activates peroxisome proliferator-activated receptor-α (PPAR-α) and regulates gene expression involved in lipid metabolism in PPAR α-expressing HepG2 hepatocytes. Biochem Biophys Res Commun 337, 440 445.
112. Hanhoff T, Benjamin S, Borchers T Spener F (2005) Branched-chain fatty acids as activators of peroxisome proliferator-activated receptors. Eur J Lipid Sci Technol 107, 716 729.
113. Hanhoff T, Wolfrum C, Ellinghaus P, Seedorf U Spener F (2001) Pristanic acid is activator of peroxisome proliferator activated receptor-α. Eur J Lipid Sci Technol 103, 75 80.
114. Gloerich J, van Vlies N, Jansen GA, Denis S, Ruiter JPN, van Werkhoven MA, Duran M, Vaz FM, Wanders RJA Ferdinandusse S (2005) A phytol-enriched diet induces changes in fatty acid metabolism in mice both via PPAR α-dependent and -independent pathways. J Lipid Res 46, 716 726.
115. McCarty MF (2001) The chlorophyll metabolite phytanic acid is a natural rexinoid - potential for treatment and prevention of diabetes. Med Hypotheses 56, 217 219.
116. Lemotte PK, Keidel S Apfel CM (1996) Phytanic acid is a retinoid X receptor ligand. Eur J Biochem 236, 328 333.
117. Kitareewan S, Burka LT, Tomer KB, Parker CE, Deterding LJ, Stevens RD, Forman BM, Mais DE, Heyman RA, McMorris T et al. (1996) Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol Biol Cell 7, 1153 1166.
118. Schluter A, Barbera MJ, Iglesias R, Giralt M Villarroya F (2002) Phytanic acid, a novel activator of uncoupling protein-1 gene transcription and brown adipocyte differentiation. Biochem J 362, 61 69.
119. Kopelovich K, Fay JR, Glazer RL Crowell JA (2002) Peroxisome proliferation-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 1, 357 363.
120. Taichman RS, Loberg RD, Mehra R Pienta KJ (2007) The evolving biology and treatment of prostate cancer. J Clin Invest 117, 2351 2359.
121. Walsh PC (2005) Serum levels of phytanic acid are associated with prostate cancer risk. J Urol 174, 1824 1824.
122. Baldwin EJ, Harley C, Gibberd FB, Wierzbicki AS Feher MD (2006) Adult Refsum's disease - diet modification results in sustained reduction in phytanic acid and absence of acute complications. J Inherit Metab Dis 29, 39 39.
123. Brown PJ, Mei G, Gibberd FB, Burston D, Mayne PD, McClinchy JE Sidey M (1993) Diet and Refsums disease - the determination of phytanic acid and phytol in certain foods and the application of this knowledge to the choice of suitable convenience foods for patients with Refsums disease. J Human Nutr Dietetics 6, 295 305.
124. Dry J, Pradalier A Canny M (1982) Refsums disease - 10 years of diet with a low phytol and phytanic acid content. Ann Med Interne 133, 483 487.